【Good News】Haibu Pharmaceutical₹ 's pregabalin oral solution•' has obtained a production license.

Classification:

Company News

Release time:

2024-10-18

Indications

This product is used for≥✔Ω‌ the treatment ofpostherpetic neuralgia£'‌;fibromyalgia;as an adjunctive treatment for p  πartial seizures in adults.

Product Advantages

Significant clinical efficacy:Pregabalin has been app÷™€≈roved globally for multi₽£♣πple indications, including postherφ♥©♦petic neuralgia, fibromyalgia, neuropat÷<¶hic pain due to spinal cor☆±÷d injury, diabetic pe©∏γripheral neuropathy, and as anφ₽γ♣ adjunct therapy for→♠α¥ partial seizures lasting one monthβ↔‍ or more. Both domestic↓≠ ¶ and international guidelines ∞₽consistently recommen✘✔​£d Pregabalin as the f &irst-line preferred medication <♠∞for treating postherpetic neuralgia (×♥PHN) and fibromyalgia (FM).

Good market prospects:Ruianxi(®)is a strawberry-flavored oral solut‍♠​ion that is convenient fo‌​•r children and patients with s¶γ'±wallowing difficulties, which helps imp¥÷↓αrove patient compliance; our companβ☆₹©y’s product is equippδ>ed with a precise dosing de©÷♦±vice, making it easier to adjust dosδα$•ages for special populations ₹™♦&and ensuring high medication adherence.<  It is a multi-indicat←≈ion drug with broad usag✘₩e, classified as a Categ±≠ory B product under medical ins↑←urance, with high demand and ✘×βgood market prospects.

 

Mechanism of Action

Pregabalin is an analogue of theγ∞ neurotransmitter gamma-a'•minobutyric acid (GABA). It reduc™λes depolarization at≠ ≈& nerve terminals and calci δ♦um ion influx by binding to≠₹ and inhibiting the α2-δ subuni ∑≥t protein of voltage-ga♥ ÷εted calcium channels, thereby in§✘hibiting the release of excitatory ≠±→neurotransmitters such as L-glutam$₩±£ate (associated with seizures✔‌, pain, and anxiety).

 

Beijing Haibu Pharmaceuticalα≤β≠ Technology Co., Ltd. (referr←¥✘ed to as 'Haibu Pharmaceuβ₹>¥tical') was established in≥★β✔ 2005 and is a high-tech enterpr§π§ise focused on 'chemica≠®☆®l drug research and develop←↑•‍ment' as its core caφ​✔αpability. It has established a >$™Ωresearch center in Beijing, an API an×↕★"d formulation pilot verification cente↕$₽r, and a GMP industrial production baε¥↑¥se. Mainly engaged in'technical development and transfeβ≥r of chemical drugs,→ε✘∑ MAH research and holdφ←ing certificates, API-related ap•↔plications, as well as commercial≥β←← supply of pharmaceutical interme♣₩©diates', 'innovation and im$≤✘₽provement drug R&D applicatio ±ns', etc., having been awarded the t‌>itle of 'Top 20 Chin ∑​ese Pharmaceutical R&•♥↔;D Companies' for several conse♦∞™Ωcutive years. It has been recog ↕≥↑nized as a 'Beijing Science and Tech♣ ♠nology Research Devel ✔↓ opment Institution', 'National Hi>÷✘gh-tech Enterprise', 'Beijing Yiz≥•huang Enterprise Innovation Center'.、創新與改良藥物(wù)研發申報(bào)等，連續多(duō)年♥±§<(nián)獲得(de)“中國(guó)醫(yī)藥研✔"←≤發公司20強”稱号，被評為(wèi)“北(běi)京科↓→'‍(kē)技(jì)研究開(kāi)發機(jī)構”、“國(γλguó)家(jiā)高(gāo)新技(jì)術(shù)企業(yè)”、“北$♣©(běi)京亦莊企業(yè)創新中心”。
'Haibu Pharmaceutical has rich ex"¶perience in the R&D tr¶↓♦εansfer production registration appli∏¥cation of various do↓¶ sage forms such as chemic‍→✘>al raw materials, oral solids, liquid pφ♦reparations, sterile injec ♠tions, external preparations. The R&↓♦;D products cover multiple i↕∑ndication areas including anti-tumor, a$÷×nti-depression, anti-epilepsy, aλ¥&nti-anxiety, cardiovasλ∏₹←cular cerebrovascular d₩×iseases, digestive system ↔↓→®diseases, respiratory system dis¥←eases.'